Clinical Trial Update: Inducing Remission in Type 1 Diabetes With Alefacept [Phase 2]

View source ↗

Summary

A Phase 2 trial of alefacept for inducing remission in new-onset type 1 diabetes was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Amevive (alefacept)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: New-onset Type 1 Diabetes Mellitus | Phase 2 | Status: TERMINATED | Results posted: 2015-01-07